This combined viro-immunotherapeutic approach synergizes to overcome adaptive immune resistance induced by intratumoral PD-1 expressing CD8+ T cells, leading to an effective IFNγ-mediated antitumor immune response and long-term cure of glioma-bearing mice. The gene discussed is IFNG; the disease is central nervous system cancer.